Lycopodium

Lycopodium (Lycopodium clavatum L.): A Comprehensive Reference

1. Identity: Botanical Classification, Common Names, and Natural Source

Lycopodium clavatum L. is a perennial evergreen plant that grows in pastures, woodlands, heaths, and moors of Great Britain, Northern Europe, and North America. It has a slender stem that trails along the ground and vertical branches that grow to 3–4 inches (7.5–10 cm). The plant belongs to the family Lycopodiaceae and is related to mosses and ferns.

Lycopodium clavatum is a species of club moss, an ancient group of plants that evolved nearly 400 million years ago. Fossils show that these primitive plants were once as tall as trees, but now they are found lying low on the forest floor. Despite their common name, club mosses are not true mosses at all.

Lycopodium is a low-creeping perennial plant. It is a spore-bearing, flowerless, vascular, terrestrial, widely branched plant. Its stems are erect and have small, simple, needle-like leaves that cover the stem and branches thickly. Kidney-shaped cases include spores of one kind only and are borne on the upper surface of the leaf blade of specialized leaves. These are arranged in a cone-like strobilus at the end of the upright stems. The club-shaped appearance of these flowering stems gives clubmosses their common name.

Lycopodium is a genus of club mosses classified under the family Lycopodiaceae, a family of diverse vascular plants. The species of the genus are endemic to tropical and temperate climates and are identified as non-flowering, terrestrial or epiphytic plants with needle- or scale-like leaves covering stems and branches.

Common Names and Synonyms

• The plant is commonly called "club moss"; other names include wolf's claw, stag horn, witch meal, and vegetable sulfur.
• It is also commonly referred to as wolf's paw or stag's horn moss.
• The spores, when collected and dried, produce a very fine, odorless powder known historically as "vegetable sulfur."

Geographic Distribution

Lycopodium clavatum (club mosses) is abundant in Europe, Asia, and North and South America. It is commonly found in the hilly pastures and heaths of Central and Northern Europe, Russian Asia, and North America.

Parts Used and Common Preparations

The fertile segments bear club-shaped strobili (cones) that release dusty yellow spores—hence the nickname "club moss." In Ayurveda, both the aerial stems and spores (spore powder) are used, though spores require careful handling due to their fine texture.

In homeopathic and traditional preparations, the plant is used in four main forms: trituration of spores, tincture of spores, tincture of the fresh plant, and ethereal tincture of spores (ether dissolves the spore cases).

Homeopathic Lycopodium clavatum is prepared from a tincture of the dried spores. The pale yellow pollen collected from the spores is used to make the homeopathic remedy called lycopodium. The pollen is odorless, water resistant, and highly flammable.

The spore powder is still in use today as a sweat-absorbing ingredient in deodorants and makeup. Due to its highly flammable nature, the powder was formerly a component of fireworks.

---

2. Traditional and Historical Use

Indigenous and Native American Use

Native American tribes employed L. clavatum in wound care; the standard treatment for injuries and lesions was the application of spores in the open wound. The spores of Lycopodium clavatum are also used routinely by Native Americans in treating nosebleeds and healing wounds.

Members of the Blackfoot tribe used Lycopodium complanatum for the treatment of pulmonary disease, while Iroquois believed in the ability of the plant to induce pregnancy.

European Folk and Herbal Use

Medicinally, Native Americans and Europeans steeped the leaves into a tea for treating pain and fever. The plant's spores were also taken internally to treat diarrhea, dysentery, and gas, and applied externally on rashes and wounds for healing.

In medieval Europe, herbalists employed "wolf's claw" powder as a wound-dressing powder, thanks to its absorbent spores.

In Turkey, Lycopodium clavatum, the most common species in Anatolia, has been reported to be used for wound-healing as well as against nappy rash in babies, and is therefore also called "belly powder." The spores of the plant were also stated to have a protective effect as a dusting powder for tender skin. In Papua New Guinea, L. clavatum is used against stomach pain.

South American Traditional Medicine

Both Lycopodium clavatum and Lycopodium thyoides have been used in South American folk medicine for central nervous system conditions. The aerial parts of plants, especially Lycopodium clavatum, are used as laxatives and diuretics, while they are commonly utilized as an aphrodisiac in South America. There are also reports of the use of some Lycopodium species in Southeast Asia and in the USA as an analgesic remedy to relieve rheumatic and muscle pains.

Chinese and East Asian Traditional Medicine

A great number of plants, such as Huperzia serrata (Qian Ceng Ta), have been used in Chinese folk medicine to treat many disorders, including contusions, swellings, fever, and blood disorders. These club mosses have been used for millennia for the treatment of a wide range of ailments in traditional folk medicines—from controlling fever to schizophrenia to memory loss.

Homeopathic Tradition

The original pathogenic trial (proving) of Lycopodium was performed by Samuel Hahnemann in 1828. In homeopathic Materia Medica, Lyc is said to have effects on liver failure and biliary stones.

In homeopathy, it is considered a polychrest—a remedy with widespread effect on various types of diseases, including liver alterations. In homeopathy, Lycopodium is recognized for its profound action on the digestive system, nervous system, and metabolism, making it an essential remedy for chronic conditions. It is particularly associated with gastrointestinal complaints, urinary disorders, and constitutional weaknesses.

Homeopathic preparations of Lycopodium are prepared using a process of trituration—grinding a substance to increase its potency—and succussion, the vigorous shaking of a substance, which is an essential process for potentizing remedies in homeopathy. The 6C dilution is a popular choice for gas pain relief, especially for gas caused by intolerance to onions and garlic, or from bloating associated with acid indigestion, according to homeopathic tradition. It must be noted that such claims are based on traditional homeopathic practice, not accepted medical evidence, and are not FDA evaluated.

---

3. Key Constituents and Active Compounds

Alkaloids: The Primary Bioactive Class

Plant species from the club moss genus Lycopodium and Huperzia (Lycopodiaceae) are known to be a rich source of compounds belonging to the alkaloid group, possessing unique heterocyclic skeletons usually containing C₁₅N₂, C₁₆N, C₁₆N₂, and C₂₇N₃. The alkaloids are quinolizine-, pyridine-, and α-pyridone-type structures.

The plant mainly contains alkaloids and triterpenoids. Alkaloids are divided into four structural types, including lycopodine, lycodine, fawcettimine, and miscellaneous.

Lycopodine is the most abundant and well-characterized alkaloid of the species. Lycopodine is the most abundant alkaloid commonly found in Lycopodium clavatum. This compound has been detected in each solvent system tested and constituted a high percentage of isolated alkaloid extracts; the lycopodine content even exceeded half of the percentage of all isolated alkaloids. Gas chromatographic–mass spectrophotometric analysis of the active alkaloid fraction confirmed that lycopodine (84.5%) is the major component.

In 1938, Achmatowicz and Uzięb\lo investigated constituents of the species L. clavatum and were able to isolate lycopodine along with clavatine and clavatoxine. Later in 1944, L. clavatum L. of North American origin was examined and found to contain nicotine, lycopodine, and clavolonine.

Other identified alkaloids from L. clavatum include clavatine, clavatoxine, nicotine, as well as polyphenolic acids including dihydrocaffeic acid, flavonoids including apigenin, and triterpenes.

More recently, two new alkaloids, lycoclavatumide (belonging to the fawcettimine class) and 8β,11α-dihydroxylycopodine, were isolated from L. clavatum collected in northern Thailand.

The Huperzine A Connection

Huperzine A, derived from the Chinese herb Huperzia serrata, was identified by scientists in China in the 1980s as a potent, reversible, selective inhibitor of acetylcholinesterase (AChE), which has a mechanism of action similar to donepezil, rivastigmine, and galantamine. Although huperzine A is predominantly associated with Huperzia serrata, which is closely related to the Lycopodium genus within Lycopodiaceae, the alkaloid research on the broader family has greatly informed understanding of L. clavatum alkaloids.

Non-Alkaloid Constituents

The spores of Lycopodium clavatum contain organic acids (such as sporonin, malic, and caffeic acids), resins, flavonoids, and alkaloids. Lycopodium has been well characterized to contain alkaloids and triterpenoids as major constituents, and these compounds have received attention for their potential pharmacological properties.

Key bioactive components include lycopodane-type alkaloids, triterpenoids, flavonoids, and phenolics.

---

4. Mechanisms of Action

Acetylcholinesterase (AChE) Inhibition

The alkaloids of Lycopodiaceae possess numerous properties such as anti-inflammatory, antioxidant, anticancer, and antimicrobial activities. In addition, they are known for important bioactivities such as the ability to inhibit acetylcholinesterase (AChE), an enzyme responsible for decreasing the concentration of the neurotransmitter acetylcholine at the synaptic site in the brain.

Huperzine A (the principal AChE-inhibiting alkaloid from the Lycopodiaceae family) is a potent, reversible, and selective inhibitor of AChE with rapid absorption and penetration into the brain. It exhibits memory-enhancing activities in animal and clinical trials. Compared to tacrine and donepezil, huperzine A possesses a longer duration of action and higher therapeutic index, and peripheral cholinergic side effects are minimal at therapeutic doses.

Research has shown that the biological properties of the folk medicinal plants Lycopodium clavatum and Lycopodium thyoides include AChE inhibitory activity and antioxidant effects—two possible mechanisms of action in Alzheimer's-related processes.

Anti-inflammatory Activity

Studies on extracts from the aerial parts of Lycopodium clavatum using an acetic acid-induced increase in capillary permeability assessment in mice revealed that only the chloroform extract and the alkaloid fraction displayed a marked anti-inflammatory effect, supporting the folk medicinal utilization of the plant. Bioassay-guided fractionation of the alkaloid fraction of Lycopodium clavatum revealed that the alkaloidal-type compounds might possibly be responsible for the anti-inflammatory activity of the extract.

Antioxidant Activity

Lycopodium has been demonstrated to possess anticancer, antioxidant, and anti-inflammatory properties. Huperzine A has been shown to have the ability to protect cells against hydrogen peroxide, beta-amyloid protein, glutamate, ischemia, and staurosporine-induced cytotoxicity and apoptosis.

Antimicrobial Activity

In vitro studies have shown noteworthy activity against Staphylococcus aureus (ATCC strain, MIC 4 µg/ml), while L. clavatum extracts also showed reasonable antifungal effect. The chloroform extract was found to be active against herpes simplex virus (16–8 µg/ml), while petroleum ether and alkaloid extracts potently inhibited parainfluenza virus type 3 (PI-3).

---

5. Scientific Evidence by Area of Use

5.1 Cognitive Function, Memory, and Neurodegeneration

Huperzine A (Lycopodiaceae family): The most clinically studied neurological application relates to huperzine A, derived from the closely related Huperzia serrata. A 2013 systematic review and meta-analysis identified 20 RCTs including 1,823 participants. The methodological quality of most included trials had a high risk of bias. Compared with placebo, huperzine A showed a significant beneficial effect on the improvement of cognitive function as measured by the Mini-Mental State Examination (MMSE) at 8, 12, and 16 weeks.

A Cochrane-methodology review found six trials including a total of 454 patients. The methodological quality of most included trials was not high. The authors concluded that huperzine A seems to have some beneficial effects on improvement of general cognitive function, global clinical status, behavioral disturbance, and functional performance, with no obvious serious adverse events for patients with AD. However, only one study was of adequate quality and size, and there is therefore inadequate evidence to make any recommendation about its use. Rigorous, randomized, multi-centre, large-sample trials are needed.

A Phase II clinical trial found that huperzine A 200 µg twice daily did not influence change in ADAS-Cog at 16 weeks. However, in secondary analyses, huperzine A 400 µg twice daily showed a 2.27-point improvement in ADAS-Cog at 11 weeks versus a 0.29-point decline in the placebo group (p = 0.001). The primary efficacy analysis did not show cognitive benefit with huperzine A 200 µg BID; the study provides Class III evidence that huperzine A 200 µg BID has no demonstrable cognitive effect in patients with mild to moderate AD.

A separate meta-analysis identified eight AD trials with 733 participants and two vascular dementia (VD) trials with 92 participants. The results showed that huperzine A could significantly improve the MMSE and Activities of Daily Living (ADL) scores of AD and VD patients, and that longer treatment durations resulted in better efficacy for patients with AD.

Evidence summary for cognition: The evidence for the broader Lycopodiaceae family's alkaloids (principally huperzine A from Huperzia serrata) on cognitive function is preliminary to moderate — positive signals in multiple meta-analyses, but with high risk of bias and mostly short trial durations. The duration of treatment in most trials was 8–12 weeks; the included trials used different doses of huperzine A, varying from 0.2 mg to 0.8 mg daily. There are no equivalent-quality human clinical trials specifically for L. clavatum preparations.

Animal model evidence for L. clavatum specifically: A study evaluated the effect of Lycopodium clavatum mother tincture and potencies (30, 200, and 1000) on learning and memory functions and cerebral blood flow in intracerebroventricularly administered streptozotocin-induced memory impairment in rats. AChE inhibitory activity had been found in Lyc alkaloid extract, which could be beneficial in dementia, but the effect of Lyc had not yet been explored in an animal model of memory impairment. That study suggested that Lyc may be useful in conditions of memory impairment due to its beneficial effect on cerebral blood flow. This is animal-level evidence only and cannot be extrapolated to humans without further clinical investigation.

5.2 Anti-Inflammatory Effects

Studies on four extracts (petroleum ether, chloroform, ethyl acetate, and methanol) as well as the alkaloid fraction from the aerial parts of Lycopodium clavatum L. of Turkish origin using acetic acid-induced increase in capillary permeability assessment in mice revealed that only the chloroform extract and the alkaloid fraction displayed a marked anti-inflammatory effect at a dose of 500 mg/kg, achieving 24.3% and 32.1% inhibition, respectively, compared to indomethacin, which exhibited 44.6% inhibition at 10 mg/kg.

A more recent animal study using a rat model of acetic acid-induced colitis (an experimental model of inflammatory bowel disease) found that treatment with Lycopodium significantly improved IBD-induced reduction in body weight, improved histology, inhibited malondialdehyde (MDA) formation, and restored antioxidants along with reduced myeloperoxidase (MPO) activity. The model showed that acetic acid caused the release of proinflammatory cytokines including interleukin-1β (IL-1β) and interleukin-23 (IL-23), which were modulated by treatment.

Evidence summary: Anti-inflammatory evidence for L. clavatum is preliminary and restricted to in vivo animal models and in vitro bioassays. No human clinical trials are available for this indication.

5.3 Hepatoprotective Effects

The original homeopathic proving of Lycopodium was performed by Samuel Hahnemann in 1828. In homeopathic Materia Medica, Lyc is said to have effects on liver failure and biliary stones.

In a peer-reviewed animal study, the effectiveness of Lycopodium clavatum 30C (Lyc) as a hepatoprotector was evaluated against liver damage experimentally induced by paracetamol (Pct) in Wistar rats. Thirty animals were subdivided into 6 groups; treated groups were pretreated for 8 days with Lyc 30c (0.25 ml/day), receiving a dose of 3 g/kg of Pct on the 8th day. A positive control group received 30% ethanol in place of Lyc 30c, and a negative control received only 30% ethanol. After 24 and 72 hours, enzyme serum measurements (AST and ALT) and liver histological analyses were performed. Lyc 30c exerted a moderate hepatoprotective effect on acute paracetamol-induced hepatitis, mainly shown by a histological decrease in necrosis and inflammatory foci, preserved glycogen and other 1,2-glycols in zone 3, and reduced serum levels of ALT and AST.

Chronic feeding of carcinogens p-dimethylamino azobenzene and phenobarbital for 90 and 120 days elevated activities of acid and alkaline phosphatases and blood glucose and cortisol in mice. Levels of these biomarkers in both liver and spleen tissues were positively altered along with a significant reduction of tumor incidence in liver of carcinogen-intoxicated mice treated with spore extract of Lycopodium clavatum. The results were stated by the authors to validate the use of this plant extract in complementary and alternative medicines against hepatotoxicity.

Lycopodium extracts, used in alternative medicine, have shown hepatoprotective and anticancer effects for liver cancer mentioned in many studies on animal models (including rats and mice).

Evidence summary: Hepatoprotective evidence is limited to rodent models. No human clinical trials have been published. The animal data are suggestive but insufficient to draw conclusions about clinical utility.

5.4 Anticancer Activity

In a cell culture (in vitro) study, researchers investigated the cytotoxic and apoptotic effects of L. clavatum water extract and ethanol extract on MCF-7 human breast cancer cells. Results showed that LC treatment led to a dose- and time-dependent cytotoxic effect on MCF-7 cells, indicating its potential as an anticancer agent against human breast cancer.

Investigations have found that lycopodynine induces internucleosomal DNA fragmentation and chromatin condensation, increases the cell population in the sub-G1 region with a rise of reactive oxygen species, inducing cytochrome-c release and Caspase-3 activation, thereby inducing apoptosis.

Evidence summary: Anticancer evidence for L. clavatum is entirely in vitro (cell culture) or based on animal carcinogen models. No human clinical trials exist. This data should be characterized as early-stage and hypothesis-generating only.

5.5 Antimicrobial and Antiviral Activity

Extracts of L. clavatum showed noteworthy antibacterial activity against an ATCC strain of S. aureus (MIC 4 µg/ml), reasonable antifungal effect, and the chloroform extract showed activity against herpes simplex virus (16–8 µg/ml), while petroleum ether and alkaloid extracts inhibited parainfluenza virus type 3.

Evidence summary: All antimicrobial and antiviral data are from in vitro studies. No human clinical trials exist for these indications.

5.6 Digestive and Gastrointestinal Use

Plant alkaloids have been reported to reduce inflammation of the digestive system and soothe the skin, reducing its irritation and itching. The gastrointestinal applications of L. clavatum in homeopathy and traditional medicine are extensive, but though many diseased conditions are being treated with Lycopodium both in traditional and homeopathic medical systems, it has self-limitations, and its therapeutic ability needs critical evaluation. No rigorous human clinical trials are available specifically evaluating L. clavatum preparations for gastrointestinal conditions.

---

6. Body Systems and Health Areas Associated with Lycopodium

The following body systems and health areas have been associated with Lycopodium clavatum across traditional use, homeopathy, and scientific investigation:

• Central nervous system: Lycopodium alkaloids are used in the treatment of aneurysms, chronic lung and bronchial diseases, and have been explored for brain diseases. AChE inhibition is the key mechanistic rationale for cognitive and neurodegenerative applications.
• Digestive system: In homeopathic medicine, Lyc as mother tincture and in potentised strength has been used for liver function, urinary and digestive disturbances, and also for rheumatism, epilepsy, and pulmonary disorders.
• Liver and biliary system: Both traditional and experimental data associate Lycopodium with hepatoprotection and liver support.
• Urinary system: The plant constitutes an important component in traditional medicine for renal diseases, rheumatic arthritis, cystitis, and gastritis.
• Skin and integument: The dry, finely powdered spores of club moss are used to promote healing by drying excess moisture that can cause skin irritation and itching in eczema, much like cornstarch or colloidal oatmeal.
• Musculoskeletal system: Traditional use includes applications for rheumatic and muscle pains.
• Respiratory system: Traditional applications include use for pulmonary and bronchial conditions.

---

7. Dosage Forms and Doses Reported in Studies

Dosage information for Lycopodium clavatum varies considerably between the phytotherapeutic/extract context and the homeopathic context. The following are doses reported specifically in published sources:

• Anti-inflammatory (animal study): The chloroform extract and alkaloid fraction of aerial parts displayed anti-inflammatory effect at a dose of 500 mg/kg in mice.
• Hepatoprotective (animal study): Animals were pretreated for 8 days with Lyc 30c (0.25 ml/day) in the rat hepatoprotection model.
• Memory/cognitive (animal study): Male Sprague-Dawley rats were treated with Lyc Mother Tincture (MT) 30, 200, and 1000 potencies for 17 days.
• Huperzine A — clinical studies (from the closely related Lycopodiaceae): Included trials used different doses of huperzine A, varying from 0.2 mg to 0.8 mg daily. One trial reported huperzine A was generally well-tolerated at doses of up to 0.4 mg BID for 24 weeks.
• Homeopathic potencies: For aiding elimination, a second or third potency of Lycopodium is recommended in liquid form, administered 3 times a day. For deeper chronic conditions, higher potencies such as 6th to 200th can be used, depending on the severity and chronicity of the illness.

It should be noted that homeopathic dilutions (e.g., 6C, 30C, 200C) are diluted to such an extent that the pharmacological significance of the starting material becomes scientifically ambiguous; these potencies are not equivalent to conventional herbal doses of the plant.

---

8. Safety Considerations and Interactions

General Toxicity Considerations

Several researchers have reported various alkaloids derived from this plant and their therapeutic potentials; however, some reports are available on toxicity studies of alkaloids of this plant. There is a need for better understanding of its ameliorating potential and its toxic actions.

Today, Lycopodium plants and extracts are not commonly employed as herbal remedies as the side effects often exceed the benefits.

Spores vs. Whole Plant: An Important Distinction

The leaves and roots of Lycopodium plants contain toxic substances and should not be ingested; however, the spores are considered safe to use. The chemical profile of the spores differs significantly from that of the whole aerial plant, which concentrates alkaloids.

Quinolizidine and Pyridine Alkaloid Class Toxicity

Maternal consumption of plant products comprising pyridine or quinolizidine alkaloids has been linked to developmental defects in humans and animals. Because L. clavatum alkaloids include quinolizidine-type structures, this general toxicological concern is relevant when considering internal use of whole-plant extracts.

Occupational Asthma from Spore Inhalation

A clinically documented safety concern relates to respiratory sensitization. A study documented asthma following occupational exposure to Lycopodium clavatum in condom manufacturers (published in Thorax, 1993;48(7):774–775). This indicates that inhalation of Lycopodium spore dust can cause occupational asthma in susceptible individuals.

Nicotine Content

North American specimens of L. clavatum have been found to contain nicotine alongside lycopodine and other alkaloids. The presence of nicotine is relevant for interactions with nicotinic acetylcholine receptor-active drugs and warrants attention in any internal-use preparation.

Potential for Paradoxical Adverse Effects

In a study examining higher homeopathic dilutions, animals receiving L. clavatum 200dH showed more severe cortex damage (91.66–96.66%) compared to controls (55–80%) and more renal corpuscle and tubule injury; both groups presented high liver enzyme levels. The authors of this study noted that L. clavatum 200dH intensifies kidney and liver alterations in mice infected with Toxoplasma gondii and that the results reinforce caution when indicating administration schemes and dosages for ultra-diluted drugs.

Flammability

The spore powder is highly flammable and should be kept away from ignition sources. This is a relevant physical safety consideration for handling bulk spore powder.

Interactions

Given the documented AChE inhibitory activity of Lycopodiaceae alkaloids, there is a theoretical concern for pharmacodynamic interaction with other cholinesterase inhibitors (such as donepezil, rivastigmine, and galantamine) as well as with anticholinergic medications. The ability of these alkaloids to inhibit acetylcholinesterase—an enzyme responsible for decreasing the concentration of acetylcholine at the synaptic site in the brain—is well characterized. Additive cholinergic effects (excess salivation, bradycardia, gastrointestinal cramping) are plausible when combining AChE-inhibiting alkaloids with pharmaceutical cholinesterase inhibitors. However, no specific interaction studies for L. clavatum preparations in humans have been published.

---

References

• Fractionation of Lycopodiaceae Alkaloids and Evaluation of Their Anticholinesterase and Cytotoxic Activities — PMC/PubMed Central
• Optimization of Pressurized Liquid Extraction of Lycopodiaceae Alkaloids Obtained from Two Lycopodium Species — PMC/PubMed Central
• Huperzine A for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials — PMC/PubMed Central
• Huperzine A for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials — PLOS ONE
• Huperzine A for Alzheimer's disease (Cochrane-methodology review) — PubMed
• A phase II trial of huperzine A in mild to moderate Alzheimer disease — PubMed
• Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease — PubMed
• Huperzine A in the Treatment of Alzheimer's Disease and Vascular Dementia: A Meta-Analysis — PMC/PubMed Central
• Appraisal of anti-inflammatory potential of the clubmoss, Lycopodium clavatum L. — PubMed
• Lycopodium Mitigates Oxidative Stress and Inflammation in the Colonic Mucosa of Acetic Acid-Induced Colitis in Rats — PMC/PubMed Central
• Identification and Analysis of Chemical Constituents and Rat Serum Metabolites in Lycopodium clavatum Using UPLC-Q-TOF/MS — PMC/PubMed Central
• In vitro and ex vivo acetylcholinesterase and antioxidant activities of traditionally used Lycopodium species from South America — PubMed
• Hepatoprotective effect of Lycopodium clavatum 30CH on experimental model of paracetamol-induced liver damage in rats — PubMed
• Effect of homeopathic Lycopodium clavatum on memory functions and cerebral blood flow in memory-impaired rats — PubMed
• Protective potentials of a plant extract (Lycopodium clavatum) on mice chronically fed hepato-carcinogens — PubMed
• Antioxidant and antimicrobial actions of the clubmoss Lycopodium clavatum L. — ResearchGate
• A better understanding of pharmacological activities and uses of phytochemicals of Lycopodium clavatum: A review — ResearchGate
• Huperzine A in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis — NCBI Bookshelf (DARE)
• Plant Alkaloids Toxicity — StatPearls, NCBI Bookshelf
• Lycopodium — ScienceDirect Topics Overview
• Appraisal of anti-inflammatory potential of the clubmoss, Lycopodium clavatum L. — ScienceDirect / Journal of Ethnopharmacology
• Identification of some L-numbered Lycopodium alkaloids — Canadian Journal of Chemistry
• Learn About Lycopodium: Earth's Oldest Remedy for Bloating — Boiron USA
• Lycopodium — Encyclopedia.com